Cortexyme Inc. Stock News

Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Intere

Cortexyme (CRTX) said its drug COR588 was well-tolerated and safe in a single ascending dose ((SAD)) portion of a phase 1 trial.The company is developing COR588 to treat diseases…

Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.

COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.

NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.

An investigation for investors in Cortexyme, Inc. (NASDAQ:CRTX) shares over potential securities laws violations by Cortexyme, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 02/24/2022 -- Cortexyme, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Cortexyme, Inc. (NASDAQ: CRTX), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Cortexyme, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. San Francisco, CA based Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer''s disease and other degenerative disorders. On October 26, 2021, Cortexyme, Inc. issued a press release "report[ing] top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis)." The press release reported, in relevant part, that the study had failed to meet statistical significance in its co-primary endpoints of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer''s disease.

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf of Cortexyme stockholders. Our investigation concerns whether Cortexyme has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 26, 2021, Cortexyme issued a press release “report[ing

Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in re

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $CRTX #CRTX--The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their Cortexyme, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/crtx .